GLPwatch
A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity
NCT05813795 · Completed
Last updated 2026-05-28This clinical trial is testing the effects of the drug XW003 on weight loss in adults who are overweight or have obesity.
Status Completed The study has finished.
Phase Phase 3 Confirms effectiveness in a large group before approval.
Type Interventional (clinical trial)
Design Randomized, triple-blind treatment study
Participants 664 people
Who can join Ages 18–75 · all sexes
Timeline Started 2023-04 · est. completion 2024-10
Where 1 site · China
What this study is testing ClinicalTrials.gov NCT05813795 ↗
Description as written by the study sponsor.
The aim of the study is to evaluate the efficacy and safety of XW003 versus placebo in adults with overweight or obesity
Treatments tested
- Ecnoglutide Low Dosage also known as XW003 Drug
Subcutaneous Injection
- Ecnoglutide Medium Dosage also known as XW003 Drug
Subcutaneous Injection
- Ecnoglutide High Dosage also known as XW003 Drug
Subcutaneous Injection
- Placebo Drug
Subcutaneous Injection with matched volume
| Main thing measured | Percent change in body weight from baseline |
|---|---|
| Sponsor | Hangzhou Sciwind Biosciences Co., Ltd. |
| Conditions studied | Weight Management |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05813795 ↗